Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent a novel class oforal hypoglycemic agents that have demonstrated the ability to improvecardiovascular outcomes in patients with Type 2 diabetes mellitus (T2DM) andheart failure [5, 6, 7, 8]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.